While the TP53 Arg72Pro-SNP and the MDM2 SNP309 have been widely studied in numerous tumor types [33], this is – to our knowledge – the first comprehensive study determining the effect of SNPs at the 1q32-locus on the onset and event-free survival in breast cancer. This evidence concerns the gene TP53 and neoplasm.